enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study

enVVeno Medical (NVNO) announced that the U.S. Food and Drug Administration, FDA, has awarded the Company the first-ever IDE approval to proceed with a U.S. pivotal study of a non-surgical replacement venous valve. The Transcatheter Venous Valve Endoprosthesis, TAVVEB, study will evaluate the Company’s minimally invasive enVVeB. System for patients with severe deep Chronic Venous Insufficiency.